{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:48:21Z","timestamp":1788281301574,"version":"build-2803163510"},"reference-count":186,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Despite the rapid development of medicine, even nowadays, acute lymphoblastic leukemia (ALL) is still a problem for pediatric clinicians. Modern medicine has reached a limit of curability even though the recovery rate exceeds 90%. Relapse occurs in around 20% of treated patients and, regrettably, 10% of diagnosed ALL patients are still incurable. In this article, we would like to focus on the treatment resistance and disease relapse of patients with B-cell leukemia in the context of prognostic factors of ALL. We demonstrate the mechanisms of the resistance to steroid therapy and Tyrosine Kinase Inhibitors and assess the impact of genetic factors on the treatment resistance, especially TCF3::HLF translocation. We compare therapeutic protocols and decipher how cancer cells become resistant to innovative treatments\u2014including CAR-T-cell therapies and monoclonal antibodies. The comparisons made in our article help to bring closer the main factors of resistance in hematologic malignancies in the context of ALL.<\/jats:p>","DOI":"10.3390\/ijms23063067","type":"journal-article","created":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T22:29:43Z","timestamp":1647210583000},"page":"3067","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.3390","volume":"23","author":[{"given":"Krzysztof","family":"J\u0119draszek","sequence":"first","affiliation":[{"name":"Student Scientific Society of Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8641-4292","authenticated-orcid":false,"given":"Marta","family":"Malczewska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Parysek-W\u00f3jcik","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-0775","authenticated-orcid":false,"given":"Monika","family":"Lejman","sequence":"additional","affiliation":[{"name":"Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"(2021, December 04). Acute Lymphocytic Leukemia\u2014Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1055-9965.EPI-16-0520","article-title":"Cancer incidence and survival trends by subtype using data from the Surveillance Epidemiology and End Results Program, 1992\u20132013","volume":"26","author":"Noone","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41571-018-0136-6","article-title":"Somatic and germline genomics in paediatric acute lymphoblastic leukaemia","volume":"16","author":"Pui","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/BLCTT.S170351","article-title":"Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia","volume":"8","author":"Hefazi","year":"2018","journal-title":"Blood Lymphat. Cancer Targets Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","article-title":"Evolving therapy of adult acute lymphoblastic leukemia: State-of-the-art treatment and future directions","volume":"13","author":"Samra","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ped.13457","article-title":"Treatment and biology of pediatric acute lymphoblastic leukemia","volume":"60","author":"Kato","year":"2018","journal-title":"Pediatr. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00277-020-03953-3","article-title":"Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia","volume":"99","author":"Schieck","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_11","unstructured":"(2022, January 29). Treatment Protocol for Children and Adolescents with Acute Lymphoblastic Leukemia\u2014AIEOP-BFM ALL 2017\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03643276."},{"key":"ref_12","unstructured":"Jolliffe, A. (2013). United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011\u2013UKALL 2011 Trial, Version 3.0."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","article-title":"A 50-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"Pui","year":"2013","journal-title":"Semin. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/bcj.2014.72","article-title":"Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: A phase II study by the Japan Adult Leukemia Study Group","volume":"4","author":"Hayakawa","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.19.01086","article-title":"Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children\u2019s Oncology Group Trial AALL0331","volume":"38","author":"Maloney","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S1470-2045(10)70114-5","article-title":"Glucocorticoid use in acute lymphoblastic leukaemia","volume":"11","author":"Inaba","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5493\/wjem.v3.i2.21","article-title":"Steroid resistance in leukemia","volume":"3","author":"Shah","year":"2013","journal-title":"World J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/PEC.0000000000001371","article-title":"Dexamethasone Compared to Prednisone for the Treatment of Children With Acute Asthma Exacerbations","volume":"34","author":"Abaya","year":"2018","journal-title":"Pediatr. Emerg. Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1210\/jc.2005-1042","article-title":"Expression of the human glucocorticoid receptor splice variants alpha, beta, and P in peripheral blood mononuclear leukocytes in healthy controls and in patients with hyper- and hypocortisolism","volume":"90","author":"Hagendorf","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/318635a0","article-title":"Primary structure and expression of a functional human glucocorticoid receptor cDNA","volume":"318","author":"Hollenberg","year":"1985","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1096\/fj.06-6214fje","article-title":"Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor","volume":"20","author":"Schmidt","year":"2006","journal-title":"FASEB J."},{"key":"ref_24","first-page":"331","article-title":"Polymorphisms in Genes Involved in the Corticosteroid Response and the Outcome of Childhood Acute Lymphoblastic Leukemia","volume":"4","author":"Fleury","year":"2004","journal-title":"Am. J. Pharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.leukres.2009.08.007","article-title":"Polymorphisms in glucocorticoid receptor gene and the outcome of childhood acute lymphoblastic leukemia (ALL)","volume":"34","author":"Labuda","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ccell.2018.11.011","article-title":"Cancer Cell Previews Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: BIM Finally","volume":"34","author":"Brown","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1083\/jcb.200108084","article-title":"FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: Protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity","volume":"156","author":"Dijkers","year":"2002","journal-title":"J. Cell Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/0888-7543(89)90287-5","article-title":"The glucocorticoid receptor gene is in 5q31-q32 [corrected]","volume":"4","author":"Francke","year":"1989","journal-title":"Genomics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000132846","article-title":"The human mineralocorticoid receptor gene (MLR) is located on chromosome 4 at q31.2","volume":"52","author":"Fan","year":"1989","journal-title":"Cytogenet. Cell Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000134062","article-title":"Localization of human CREBBP (CREB binding protein) to 16p13.3 by fluorescence in situ hybridization","volume":"71","author":"Chen","year":"1995","journal-title":"Cytogenet. Genome Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/hmg\/7.7.1071","article-title":"WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma","volume":"7","author":"Stec","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fcvm.2020.00135","article-title":"Studies in Zebrafish Demonstrate That CNNM2 and NT5C2 Are Most Likely the Causal Genes at the Blood Pressure-Associated Locus on Human Chromosome 10q24.32","volume":"7","author":"Vishnolia","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0888-7543(90)90043-T","article-title":"Cloning of cDNAs for human phosphoribosylpyrophosphate synthetases 1 and 2 and X chromosome localization of PRPS1 and PRPS2 genes","volume":"8","author":"Becker","year":"1990","journal-title":"Genomics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1126\/science.7604266","article-title":"Mutations of GTBP in genetically unstable cells","volume":"268","author":"Papadopoulos","year":"1995","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/371075a0","article-title":"Mutations of two PMS homologues in hereditary nonpolyposis colon cancer","volume":"371","author":"Nicolaides","year":"1994","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/320084a0","article-title":"Localization of gene for human p53 tumour antigen to band 17p13","volume":"320","author":"Isobe","year":"1986","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature09727","article-title":"CREBBP mutations in relapsed acute lymphoblastic leukaemia","volume":"471","author":"Mullighan","year":"2011","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/sj.onc.1203562","article-title":"CBP\/p300 histone acetyl-transferase activity is important for the G1\/S transition","volume":"19","author":"Polesskaya","year":"2000","journal-title":"Oncogene"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"173050","DOI":"10.1016\/j.ejphar.2020.173050","article-title":"Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-\u03baB and autophagy on panobinostat cytotoxicity","volume":"875","author":"Mehrpouri","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"22970","DOI":"10.1074\/jbc.C115.671123","article-title":"Dihydrofolate Reductase and Thymidylate Synthase Transgenes Resistant to Methotrexate Interact to Permit Novel Transgene Regulation","volume":"290","author":"Rushworth","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1021\/acs.biochem.1c00558","article-title":"Evolution of Optimized Hydride Transfer Reaction and Overall Enzyme Turnover in Human Dihydrofolate Reductase","volume":"60","author":"Li","year":"2021","journal-title":"Biochemistry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s12031-020-01561-4","article-title":"Dihydrofolate Reductase (DHFR) del19bp Polymorphism and Down Syndrome Offspring","volume":"70","author":"Barboza","year":"2020","journal-title":"J. Mol. Neurosci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/nar\/13.6.2035","article-title":"Nucleotide sequence of a functional cDNA for human thymidylate synthase","volume":"13","author":"Takeishi","year":"1985","journal-title":"Nucleic Acids Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0065-2571(95)00004-6","article-title":"The role of thymidylate synthase in cellular regulation","volume":"36","author":"Chu","year":"1996","journal-title":"Adv. Enzym. Regul."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10637-005-4541-1","article-title":"From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates","volume":"24","author":"Walling","year":"2006","journal-title":"Investig. New Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1080\/07391102.2016.1186560","article-title":"Human dihydrofolate reductase and thymidylate synthase form a complex in vitro and co-localize in normal and cancer cells","volume":"35","author":"Antosiewicz","year":"2017","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"12074","DOI":"10.1038\/s41598-020-69059-y","article-title":"FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia","volume":"10","author":"Yu","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-015-0158-9","article-title":"Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia","volume":"8","author":"Wojtuszkiewicz","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41588-019-0372-4","article-title":"Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia","volume":"51","author":"Cortese","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1006\/bbrc.1996.1798","article-title":"Replication factor C recognizes 5\u2032-phosphate ends of telomeres","volume":"229","author":"Uchiumi","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.18632\/oncotarget.27516","article-title":"The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma","volume":"11","author":"Kinahan","year":"2020","journal-title":"Oncotarget"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/10245332.2016.1265780","article-title":"Clinical significance of the ABCB1 and ABCG2 gene expression levels in acute lymphoblastic leukemia","volume":"22","author":"Carrillo","year":"2016","journal-title":"Hematology"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Saha, V., and Kearns, P. (2011). New Agents for the Treatment of Acute Lymphoblastic Leukemia, Springer Science & Business Media.","DOI":"10.1007\/978-1-4419-8459-3"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Elens, I., Deprez, S., Billiet, T., Sleurs, C., Labarque, V., Uyttebroeck, A., Van Gool, S., Lemiere, J., and D\u2019Hooge, R. (2021). Methylene tetrahydrofolate reductase A1298C polymorphisms influence the adult sequelae of chemotherapy in childhood-leukemia survivors. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0250228"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ijc.10829","article-title":"Loss of folylpoly-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines","volume":"103","author":"Liani","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.pedneo.2014.10.006","article-title":"Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance","volume":"56","author":"Chen","year":"2015","journal-title":"Pediatr. Neonatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/BF01574256","article-title":"Assignment of structural gene for asparagine synthetase to human chromosome 7","volume":"9","author":"Arfin","year":"1983","journal-title":"Somat. Cell Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-asparaginase treatment in acute lymphoblastic leukemia","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1126\/science.160.3827.533","article-title":"Asparagine synthetase activity of mouse leukemias","volume":"160","author":"Horowitz","year":"1968","journal-title":"Science"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1182\/blood-2002-08-2446","article-title":"Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL","volume":"101","author":"Stams","year":"2003","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1042\/bj3570321","article-title":"Asparagine synthetase expression alone is sufficient to induce L-asparaginase resistance in MOLT-4 human leukaemia cells","volume":"357","author":"Aslanian","year":"2001","journal-title":"Biochem. J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/pbc.21213","article-title":"Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines","volume":"50","author":"Su","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"8068","DOI":"10.1038\/srep08068","article-title":"Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines","volume":"5","author":"Chien","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/pbc.22305","article-title":"Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia","volume":"54","author":"Cohen","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood-2019-01-852392","article-title":"Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL","volume":"133","author":"Dieck","year":"2019","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ccell.2018.06.003","article-title":"Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia","volume":"34","author":"Dieck","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nm.3840","article-title":"Negative feedback\u2013defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL","volume":"21","author":"Li","year":"2015","journal-title":"Nat. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.0306-5251.2001.01391.x","article-title":"6-Thioguanine in children with acute lymphoblastic leukaemia: Influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations","volume":"51","author":"Lancaster","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00280-009-1184-5","article-title":"DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma","volume":"66","author":"Hedeland","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3324\/haematol.2017.176362","article-title":"MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia","volume":"103","author":"Evensen","year":"2018","journal-title":"Haematologica"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1097-2765(00)80316-0","article-title":"hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched DNA","volume":"3","author":"Gradia","year":"1999","journal-title":"Mol. Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41588-019-0398-7","article-title":"SETD2 regulates the maternal epigenome, genomic imprinting and embryonic development","volume":"51","author":"Xu","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Al Sarakbi, W., Sasi, W., Jiang, W.G., Roberts, T., Newbold, R.F., and Mokbel, K. (2009). The mRNA expression of SETD2 in human breast cancer: Correlation with clinico-pathological parameters. BMC Cancer, 9.","DOI":"10.1186\/1471-2407-9-290"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1038\/ncomms4469","article-title":"Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia","volume":"5","author":"Mar","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1002\/cam4.2255","article-title":"Is hyperdiploidy a favorable cytogenetics in adults with B-lymphoblastic leukemia?","volume":"8","author":"Chen","year":"2019","journal-title":"Cancer Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/gcc.22765","article-title":"Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children","volume":"58","author":"Lavoie","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e828","DOI":"10.1016\/S2352-3026(21)00304-5","article-title":"Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: A retrospective analysis of data from the UKALL97\/99 and UKALL2003 clinical trials","volume":"8","author":"Enshaei","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"72733","DOI":"10.18632\/oncotarget.12238","article-title":"Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia","volume":"7","author":"Ojha","year":"2016","journal-title":"Oncotarget"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1556-0864(15)31506-9","article-title":"The Ras\/Raf\/MAPK Pathway","volume":"1","author":"Molina","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"9268","DOI":"10.1073\/pnas.85.23.9268","article-title":"Analysis of RAS oncogene mutations in human lymphoid malignancies","volume":"85","author":"Neri","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1126\/science.1174229","article-title":"Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells","volume":"325","author":"Yun","year":"2009","journal-title":"Science"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/jid.2013.429","article-title":"NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi","volume":"134","author":"Charbel","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"11306","DOI":"10.1073\/pnas.1608420113","article-title":"Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia","volume":"113","author":"Oshima","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/gcc.20502","article-title":"Mutations of FLT3, NRAS, KRAS, and PTPN11 are Frequent and Possibly Mutually Exclusive in High Hyperdiploid Childhood Acute Lymphoblastic Leukemia","volume":"47","author":"Paulsson","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Griffin","year":"2002","journal-title":"Blood"},{"key":"ref_87","first-page":"2823","article-title":"The histone methyltransferase DOT1L: Regulatory functions and a cancer therapy target","volume":"5","author":"Wong","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Spinella, J.F., Cassart, P., Garnier, N., Rousseau, P., Drullion, C., Richer, C., Ouimet, M., Saillour, V., Healy, J., and Autexier, C. (2015). A novel somatic mutation in ACD induces telomere lengthening and apoptosis resistance in leukemia cells. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1639-5"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1021\/acs.biochem.1c00377","article-title":"Targeted Degradation of the Oncogenic Phosphatase SHP2","volume":"60","author":"Vemulapalli","year":"2021","journal-title":"Biochemistry"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable kinase gene fusions in high-risk B-ALL: A study from the Children\u2019s Oncology Group","volume":"129","author":"Reshmi","year":"2017","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/ped.13365","article-title":"MSH2 deletion with CREBBP and KRAS mutations in pediatric high-hyperdiploid acute lymphoblastic leukemia","volume":"59","author":"Ueyama","year":"2017","journal-title":"Pediatr. Int."},{"key":"ref_92","first-page":"145","article-title":"Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer","volume":"9","author":"Sun","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1073\/pnas.87.12.4799","article-title":"Characterization of ROS1 cDNA from a human glioblastoma cell line","volume":"87","author":"Birchmeier","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ng.3362","article-title":"Genomics and drug profiling of fatal TCF3-HLF\u2212positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options","volume":"47","author":"Fischer","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V93.9.2780","article-title":"Expression of E2A-HLF Chimeric Protein Induced T-Cell Apoptosis, B-Cell Maturation Arrest, and Development of Acute Lymphoblastic Leukemia","volume":"93","author":"Honda","year":"1999","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/gcc.22998","article-title":"Cryptic TCF3 fusions in childhood leukemia: Detection by RNA sequencing","volume":"61","author":"Salim","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3109\/10428194.2011.565436","article-title":"Prognostic impact of t(1;19)\/TCF3\u2013PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin\u2013Frankfurt\u2013M\u00fcnster-based protocols","volume":"52","author":"Felice","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/imr.12206","article-title":"The regulatory network of B-cell differentiation: A focused view of early B-cell factor 1 function","volume":"261","author":"Boller","year":"2014","journal-title":"Immunol. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1101\/gad.6.9.1608","article-title":"Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia","volume":"6","author":"Hunger","year":"1992","journal-title":"Genes Dev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2014029","DOI":"10.4084\/mjhid.2014.029","article-title":"Prognostic Value of Protease Activated Receptor-1 in Children with Acute Lymphoblastic Leukemia","volume":"6","author":"Hagag","year":"2014","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_101","first-page":"321","article-title":"The E2A-HLF oncogenic fusion protein acts through Lmo2 and Bcl-2 to immortalize hematopoietic progenitors","volume":"25","author":"Yeung","year":"2010","journal-title":"Leukemia"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/335440a0","article-title":"Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells","volume":"335","author":"Vaux","year":"1988","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Lasica, M., and Anderson, M.A. (2021). Review of Venetoclax in CLL, AML and Multiple Myeloma. J. Pers. Med., 11.","DOI":"10.3390\/jpm11060463"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"89","DOI":"10.31557\/APJCP.2021.22.S1.89","article-title":"Effect of Valproic Acid on the Class I Histone Deacetylase 1, 2 and 3, Tumor Suppressor Genes p21WAF1\/CIP1 and p53, and Intrinsic Mitochondrial Apoptotic Pathway, Pro- (Bax, Bak, and Bim) and anti-(Bcl-2, Bcl-xL, and Mcl-1) Apoptotic Genes Expression, Cell Viability, and Apoptosis Induction in Hepatocellular Carcinoma HepG2 Cell Line","volume":"22","author":"Sanaei","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/35085588","article-title":"Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas","volume":"412","author":"Pasqualucci","year":"2001","journal-title":"Nature"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature05953","article-title":"Non-transcriptional control of DNA replication by c-Myc","volume":"448","author":"Ying","year":"2007","journal-title":"Nature"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1709391","DOI":"10.1080\/23723556.2019.1709391","article-title":"Targeting the oncogenic activity of TCF3-HLF in leukemia","volume":"7","author":"Huang","year":"2020","journal-title":"Mol. Cell. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1172\/JCI33032","article-title":"The legacy of the Philadelphia chromosome","volume":"117","author":"Koretzky","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40880-016-0108-0","article-title":"The Philadelphia chromosome in leukemogenesis","volume":"35","author":"Kang","year":"2016","journal-title":"Chin. J. Cancer"},{"key":"ref_111","unstructured":"Haider, M.Z., and Anwer, F. (2022, February 06). Genetics, Philadelphia Chromosome, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560689\/."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-018-0788-y","article-title":"Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products","volume":"17","author":"Siveen","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12943-018-0801-5","article-title":"Advances in studies of tyrosine kinase inhibitors and their acquired resistance","volume":"17","author":"Jiao","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved Early Event-Free Survival with Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children\u2019s Oncology Group Study","volume":"27","author":"Schultz","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","article-title":"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): A randomised, open-label, intergroup study","volume":"13","author":"Biondi","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3026(18)30173-X","article-title":"Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): A prospective, intergroup, open-label, single-arm clinical trial","volume":"5","author":"Biondi","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Zawitkowska, J., Lejman, M., P\u0142onowski, M., Bulsa, J., Szczepa\u0144ski, T., Romiszewski, M., Mizia-Malarz, A., Derwich, K., Karolczyk, G., and Ociepa, T. (2020). Clinical outcome in pediatric patients with philadelphia chromosome positive all treated with tyrosine kinase inhibitors plus chemotherapy\u2014The experience of a Polish pediatric leukemia and lymphoma study group. Cancers, 12.","DOI":"10.3390\/cancers12123751"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11899-019-00543-7","article-title":"Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors","volume":"14","author":"Yaghmaie","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","article-title":"Resistance to imatinib mesylate in chronic myeloid leukaemia","volume":"249","author":"Melo","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1517\/13543784.17.6.865","article-title":"New Bcr-Abl inhibitors in chronic myeloid leukemia: Keeping resistance in check","volume":"17","author":"Eide","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in Imatinib-Resistant Philadelphia Chromosome\u2013Positive Leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/1078-0432.CCR-19-0090","article-title":"Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia","volume":"26","author":"Hijiya","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1586\/14737140.8.9.1387","article-title":"Abl tyrosine kinase inhibitors for overriding Bcr-Abl\/T315I: From the second to third generation","volume":"8","author":"Tanaka","year":"2008","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: A single-centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1182\/blood-2019-129579","article-title":"Dynamic Evolution of Ponatinib Resistant BCR-ABL1 T315 and Compound Mutations","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.beha.2018.09.003","article-title":"Why and how to treat Ph-like ALL?","volume":"31","author":"Roberts","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/ng.2803","article-title":"Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse","volume":"45","author":"Roberts","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_134","first-page":"154","article-title":"Molecular background and therapeutic perspectives of acute lymphoblastic leukemia BCR-ABL1-like","volume":"5","author":"Pediatrii","year":"2014","journal-title":"Hematol. Clin. Pract."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"a011205","DOI":"10.1101\/cshperspect.a011205","article-title":"The JAK\/STAT Pathway","volume":"4","author":"Harrison","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fped.2017.00258","article-title":"Integration of Next-Generation Sequencing to Treat Acute Lymphoblastic Leukemia with Targetable Lesions: The St. Jude Children\u2019s Research Hospital Approach","volume":"5","author":"Inaba","year":"2017","journal-title":"Front. Pediatr."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41698-021-00215-x","article-title":"Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia","volume":"5","author":"Downes","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cancergen.2017.07.008","article-title":"A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH","volume":"216\u2013217","author":"Sadras","year":"2017","journal-title":"Cancer Genet."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.canlet.2021.04.027","article-title":"Constitutive JAK\/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia","volume":"512","author":"Eadie","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2020.11.012","article-title":"Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis","volume":"183","author":"Chen","year":"2020","journal-title":"Cell"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1212\/WNL.0000000000006642","article-title":"CSF1R-related leukoencephalopathy: A major player in primary microgliopathies","volume":"91","author":"Konno","year":"2018","journal-title":"Neurology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1182\/blood-2015-09-670166","article-title":"EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): Genetic profile and clinical implications","volume":"127","author":"Schwab","year":"2016","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2019001244","article-title":"Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements","volume":"134","author":"Tanasi","year":"2019","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e26786","DOI":"10.1002\/pbc.26786","article-title":"Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic\/cytogenetic features in children with B-precursor acute lymphoblastic leukemia","volume":"65","author":"Liang","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/asheducation-2018.1.137","article-title":"Genetics and prognosis of ALL in children vs. adults","volume":"2018","author":"Roberts","year":"2018","journal-title":"Hematology"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood.V86.1.38.bloodjournal86138","article-title":"Frequent Loss of Heterozygosity at the TEL Gene Locus in Acute Lymphoblastic Leukemia of Childhood","volume":"86","author":"Stegmaier","year":"1995","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng.3177","article-title":"Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy","volume":"47","author":"Zhang","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1006\/geno.1994.1383","article-title":"Molecular cloning of the cDNA for human TrkC (NTRK3), chromosomal assignment, and evidence for a splice variant","volume":"22","author":"McGregor","year":"1994","journal-title":"Genomics"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0092-8674(91)90442-2","article-title":"trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3","volume":"66","author":"Lamballe","year":"1991","journal-title":"Cell"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood-2018-05-849554","article-title":"ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition","volume":"132","author":"Roberts","year":"2018","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion\u2013Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_153","first-page":"312","article-title":"Blinatumomab\u2014A novel drug in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"7","author":"Ejduk","year":"2016","journal-title":"Hematol. Clin. Pract."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"101077","DOI":"10.1016\/j.tranon.2021.101077","article-title":"Abnormal alternative splicing promotes tumor resistance in targeted therapy and immunotherapy","volume":"14","author":"Deng","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1128\/MCB.17.6.3116","article-title":"Regulated expression and RNA processing of transcripts from the Srp20 splicing factor gene during the cell cycle","volume":"17","author":"Jumaa","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/nature05676","article-title":"Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements","volume":"446","author":"Lareau","year":"2007","journal-title":"Nature"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood-2019-128977","article-title":"A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R\/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children\u2019s Oncology Group Protocol AALL1621","volume":"134","author":"Ji","year":"2019","journal-title":"Blood"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani","year":"2018","journal-title":"Leukemia"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"E546","DOI":"10.1097\/MPH.0000000000001440","article-title":"Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance","volume":"41","author":"Paul","year":"2019","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00005-020-00599-x","article-title":"The Application of CAR-T Cells in Haematological Malignancies","volume":"68","author":"Skorka","year":"2020","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T Cells for Next-Generation Cancer Therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMp1711886","article-title":"Tragedy, Perseverance, and Chance\u2014The Story of CAR-T Therapy","volume":"377","author":"Rosenbaum","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/ahp-2020-0001","article-title":"Where dreams come true: CAR-T cell therapy in Poland!","volume":"51","year":"2020","journal-title":"Acta Haematol. Pol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Dombret","year":"2018","journal-title":"Blood"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.32558","article-title":"Blinatumomab compared with standard of care for the treatment of adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia","volume":"126","author":"Rambaldi","year":"2020","journal-title":"Cancer"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ajh.25274","article-title":"Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia","volume":"93","author":"Jacoby","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Panuciak, K., Margas, M., Makowska, K., and Lejman, M. (2022). Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias. Cells, 11.","DOI":"10.3390\/cells11010139"},{"key":"ref_176","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hon.2591","article-title":"CAR T-cell therapy: Full speed ahead","volume":"37","author":"Sermer","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Subklewe","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3109\/10428199609054857","article-title":"Graft-versus-leukemia effect and its clinical implications","volume":"23","author":"Imamura","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0960-9822(06)00422-2","article-title":"A novel receptor for Apo2L\/TRAIL contains a truncated death domain","volume":"7","author":"Marsters","year":"1997","journal-title":"Curr. Biol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1093\/emboj\/16.17.5386","article-title":"TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL","volume":"16","author":"Walczak","year":"1997","journal-title":"EMBO J."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1091\/mbc.e04-03-0184","article-title":"Differential Regulation of the TRAIL Death Receptors DR4 and DR5 by the Signal Recognition Particle","volume":"15","author":"Ren","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Watanabe, A., Miyake, K., Akahane, K., Goi, K., Kagami, K., Yagita, H., and Inukai, T. (2021). Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia. Genes, 12.","DOI":"10.3390\/genes12060864"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/6\/3067\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:35:27Z","timestamp":1760135727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/6\/3067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,12]]},"references-count":186,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ijms23063067"],"URL":"https:\/\/doi.org\/10.3390\/ijms23063067","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,12]]}}}